Back to Search Start Over

Merck to develop biotech generics: its first copycat drug would compete with Amgen's Aranesp and is scheduled for launch in 2012

Authors :
Rockoff, Jonathan D.
Winslow, Ron
Source :
Wall Street Journal. Europe. Dec 10, 2008, A3
Publication Year :
2008

Abstract

Pharmaceutical giant Merck & Co. is planning to form a unit, Merck BioVentures, to develop generic versions of other pharmaceutical companies' top-selling biotech drugs. Merck will invest $1.5 billion in the new venture by 2015, and launch its first biotech drug in 2012 with at least five more releases planned by 2017.

Details

Language :
English
ISSN :
09219986
Database :
Gale General OneFile
Journal :
Wall Street Journal. Europe
Publication Type :
News
Accession number :
edsgcl.191404909